ProQR Therapeutics Income Statement (2021-2025) | PRQR

1Y3Y5Y7Y10YAll
Download Data
Income Statement Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 0.17M0.29M1.03M0.27M1.27M0.99M0.82M0.73M0.70M1.31M1.49M3.53M4.83M6.79M4.22M4.60M4.75M4.32M3.37M
Operating items
Depreciation & Amortization - Total 0.76M0.72M0.64M0.63M0.64M0.63M0.62M0.76M
Research & Development -10.74M-11.72M-13.12M-14.25M-15.00M-12.22M-15.48M92.88M-6.50M-6.43M-5.93M45.80M-10.08M-7.59M-10.34M66.36M-12.96M-12.91M-12.95M
Selling, General & Administrative -4.03M-4.96M-5.41M-6.08M-5.51M-5.77M-5.40M35.03M-4.32M-4.51M-3.61M29.83M-3.75M-3.24M-3.61M25.01M-3.40M-5.45M-3.65M
Other Operating Expenses -0.76M-0.72M-0.64M-0.63M-0.64M-0.63M-0.62M-0.76M
Operating Expenses -14.77M-16.69M-18.53M-20.33M-20.51M-17.99M-20.88M127.90M-10.83M-10.95M-9.54M75.62M-13.83M-10.83M-13.94M91.38M-16.36M-18.36M-16.60M
Operating Income -14.60M-15.90M-17.17M-19.82M-19.13M-16.89M-19.99M-12.71M-10.08M-9.59M-8.05M-6.74M-8.77M-3.88M-9.57M-10.77M-11.38M-13.87M-13.19M
EBIT -14.60M-15.90M-17.17M-19.82M-19.13M-16.89M-19.99M-12.71M-10.08M-9.59M-8.05M-6.74M-8.77M-3.88M-9.57M-10.77M-11.38M-13.87M-13.19M
Non-operating items
Other Non Operating Income -0.35M-2.97M0.31M-0.34M-0.92M1.24M0.60M-0.58M0.51M0.40M0.53M0.55M0.52M0.48M0.22M0.33M
Non Operating Income 0.35M2.97M-0.31M0.34M1.41M0.13M0.63M
Net income details
EBT -14.60M-15.90M-17.17M-19.82M-19.13M-16.89M-19.99M-12.71M-10.08M-9.59M-8.05M-6.74M-8.77M-3.88M-9.57M-10.77M-11.38M-13.87M-13.19M
Profit After Tax 15.22M18.97M17.77M-20.87M-15.84M-14.39M-23.50M-13.57M-9.50M-8.69M-5.90M-5.90M-8.32M-2.90M-8.90M-9.94M-10.60M-13.79M-12.87M
Equity Income 0.13M-0.26M-0.16M0.10M-0.01M
Income from Non-Controlling Interests -0.01M-0.01M-0.03M-0.02M-0.01M0.23M0.01M-0.00M0.08M0.02M0.32M
Income from Continuing Operations -14.60M-15.90M-17.17M-19.82M-19.13M-16.89M-19.99M-12.71M-10.08M-9.59M-8.05M-6.74M-8.77M-3.88M-9.57M-10.77M-11.38M-13.87M-13.19M
Consolidated Net Income -14.60M-15.90M-17.17M-19.82M-19.13M-16.89M-19.99M-12.71M-10.08M-9.59M-8.05M-6.74M-8.77M-3.88M-9.57M-10.77M-11.38M-13.87M-13.19M
Income towards Parent Company -15.21M-19.13M-17.74M-20.84M-15.84M-14.62M-23.51M-13.57M-9.82M-8.70M-6.58M-5.31M-8.32M-2.90M-9.32M-9.84M-10.99M-14.56M-12.89M
Net Income towards Common Stockholders -15.21M-19.13M-17.74M-20.84M-15.84M-14.62M-23.51M-13.57M-9.82M-8.70M-6.58M-5.31M-8.32M-2.90M-9.32M-9.84M-10.99M-14.56M-12.89M
Additional items
EPS (Basic) -0.05M-0.03M-0.02M-0.28-0.07M-0.04M-0.03M-0.19-0.08M-0.04M-0.02M-0.06-0.09M-0.02M-0.04M-0.11-0.10M-0.06M-0.03M
EPS (Weighted Average and Diluted) -0.05M-0.03M-0.02M-0.02M-0.07M-0.04M-0.03M-0.19-0.08M-0.04M-0.02M-0.06-0.09M-0.02M-0.04M-0.11-0.10M-0.06M-0.03M
Shares Outstanding (Weighted Average) 301.56578.05825.5073.42M224.47416.15725.9673.09M118.07228.67304.8187.16M97.77140.00252.5991.99M105.19237.71374.10
Shares Outstanding (Diluted Average) 301.56578.05825.500.00M224.47416.15725.9673.09M118.07228.67304.8187.16M97.77140.00252.5991.99M105.19237.71374.10
EBITDA 14.74M19.14M17.53M-20.69M15.59M13.65M22.88M-11.95M9.74M-8.68M-6.26M-6.74M8.11M2.81M9.32M-10.77M10.99M14.56M12.89M